Mutations in the IDH2 gene have been identified in various types of cancer, including acute myeloid leukemia (AML), cholangiocarcinoma, and gliomas. These mutations often lead to the production of an aberrant enzyme that converts α-KG to 2-hydroxyglutarate (2-HG), an oncometabolite that disrupts cellular function and promotes tumorigenesis.
